Laxative Abuse

Laxative abuse is the deliberate, excessive or inappropriate use of laxative medications. It is most commonly a compensatory purging behaviour in an eating disorder, particularly bulimia nervosa and the binge purge subtype of anorexia nervosa. It also occurs in isolation without a broader eating disorder.

It is driven by a mistaken belief that laxatives are effective for weight control. In reality, laxative induced weight loss reflects predominantly transient fluid and stool mass loss rather than genuine, sustained caloric malabsorption or fat loss.

The behaviour therefore carries substantial medical risk without the perceived weight control benefit that typically motivates it. This is an important point for patient education and engagement.

Pathophysiology

• Stimulant laxatives (including senna and bisacodyl) are the class most frequently misused, given their potent, rapid effect. They act directly on the colonic mucosa to stimulate motility and secretion, producing rapid, often substantial watery stool output.
• Users frequently misinterpret this output as genuine caloric or fat loss. In reality the great majority of ingested calories have already been absorbed in the small intestine before the laxative effect occurs in the colon.
• Chronic misuse causes significant fluid and electrolyte loss. Potassium loss is particularly prominent, from direct secretory loss and from chronic volume depletion activating the renin angiotensin aldosterone system, which drives further renal potassium wasting.
• With prolonged use there is a risk of laxative dependency. Chronic stimulant laxative use produces progressive colonic dysmotility and reduced bowel responsiveness, driving escalating laxative requirement.
• On attempted discontinuation there is significant, often alarming rebound fluid retention and constipation. This can reinforce continued misuse if not anticipated and explained to the patient.

• Chronic or recurrent diarrhoea, with abdominal pain and bloating, are the direct gastrointestinal manifestations. Pattern and severity reflect the laxative agent, dose and frequency of use.
• Fluid and electrolyte disturbance causes postural dizziness and hypotension (volume depletion), muscle weakness and cramping (hypokalaemia), and in more severe cases cardiac arrhythmia. These are potentially serious systemic manifestations needing active clinical assessment.
• Rebound oedema and constipation occur on attempted discontinuation of chronic laxative use. They reflect physiological adaptation and the secondary hyperaldosteronism that develops with sustained volume depletion.
• Proactive patient education is needed, as this phase can precipitate resumption of laxative use if the patient is not prepared and reassured that it is expected and generally transient.
• Eating disorder is frequently associated, so assess sensitively for the broader features and risks of disordered eating (see eating disorders).
• Ask directly about laxative use, which patients may not disclose spontaneously through shame or lack of recognition of its harm. Include this in the assessment of any patient with a compatible pattern of symptoms or an established or suspected eating disorder.

• Diagnosis relies substantially on a detailed, non-judgmental clinical history with direct enquiry about laxative use, as patients are often reluctant to disclose it spontaneously. Assess the broader eating disorder context where relevant.
• Electrolyte assessment is essential, including potassium, magnesium and bicarbonate. Metabolic alkalosis is a recognised finding, reflecting gastrointestinal bicarbonate loss combined with secondary hyperaldosteronism.
• This distinguishes the typical biochemical pattern from the metabolic acidosis more characteristic of genuine, severe diarrhoeal illness from an infective or inflammatory cause.
• Assess renal function too, given the risk of pre-renal impairment from significant volume depletion.
• Where the diagnosis is uncertain, or alternative or coexisting gastrointestinal pathology is a consideration, further investigation (stool studies and, where indicated, colonoscopy) may exclude other explanations for chronic diarrhoea. The diagnosis is frequently established primarily through the history once it is directly explored.
• Urinary or, where available, specific laxative screening (identifying laxative metabolites) may occasionally be used in diagnostic uncertainty or where the history is inconsistent with the clinical picture. It is not routinely required where the history is clear and consistent.

• Gradual, structured laxative withdrawal is generally recommended rather than abrupt discontinuation, given the risk of significant, distressing rebound symptoms with sudden cessation. Individualise the tapering approach to the pattern and duration of use.
• Educate the patient proactively about the expected, generally transient phase of rebound fluid retention and constipation. This is essential to supporting successful discontinuation.
• Correct any significant electrolyte disturbance, particularly hypokalaemia, by standard principles for that derangement. Attend to the underlying volume status, as secondary hyperaldosteronism can complicate straightforward correction in some patients.
• Managing the frequently associated eating disorder, where present, is essential and is the more fundamental therapeutic priority (see eating disorders and, most commonly, bulimia nervosa). Addressing laxative use in isolation, without the underlying eating disorder and its psychological drivers, is unlikely to achieve durable resolution.
• Psychoeducation should state that laxative use does not produce genuine, sustained caloric or fat loss. It reflects predominantly transient fluid and stool mass loss. This directly addresses the mistaken belief that underlies and perpetuates the behaviour.
• Where genuine constipation requiring treatment coexists, either as a separate issue or as part of the expected rebound pattern after discontinuation, osmotic laxatives (such as macrogol preparations) are generally preferred over stimulant laxatives. They have a more physiological mechanism and substantially lower dependency and misuse potential.
• Support normal bowel function during and after withdrawal with dietary and lifestyle measures: adequate fluid and fibre intake, and regular physical activity where appropriate given the broader clinical context.
• Ongoing, coordinated multidisciplinary support underpins effective management. It incorporates medical monitoring, nutritional guidance, and psychological treatment of any underlying eating disorder or other psychological drivers.
• A non-judgmental, collaborative approach is essential, given the frequent shame and secrecy surrounding this behaviour.